Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma.
about
Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapyNovel delivery strategies for glioblastomaIL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cellsExpression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo.Herpes simplex virus oncolytic therapy for pediatric malignanciesEvaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates.Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry.Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates.Genetically engineered HSV in the treatment of glioma: a review.A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animalsToxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma.HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applicationsDevelopment of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy.Current status of viral gene therapy for brain tumours.Herpes simplex viruses: is a vaccine tenable?Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 15-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancerTreatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47deltaEngineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1Genetic metamorphosis of herpes simplex virus-1 into a biological therapeutic for human cancer.Genetically engineered herpes simplex viral vectors in the treatment of brain tumors: a review.Design and application of oncolytic HSV vectors for glioblastoma therapy.Oncolytic herpes viruses as a potential mechanism for cancer therapy.Gene therapy for malignant glioma.Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma modelConditionally replicative adenovirus for gastrointestinal cancers.Oncolytic viral therapies.Novel therapies in glioblastoma.The range and distribution of murine central nervous system cells infected with the gamma(1)34.5- mutant of herpes simplex virus 1.Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate.Replication-competent herpes simplex vectors: design and applications.To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control.Herpes simplex virus 1 (HSV-1) for cancer treatment.Preclinical evaluation of oncolytic δγ(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastasesPediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy
P2860
Q24679781-E7D1318C-B3E7-44D2-91AD-FDF3CE4A3AF1Q27006099-A7BB23CC-95A2-4511-BDEF-08D0A480CD84Q30355682-E0A5CE7D-3524-4AF4-B889-327854742D65Q33649894-CD5E957E-9BA1-4300-ADFD-B9D3A89204BEQ33690926-200C4647-9A7C-4228-B2DE-640CCFBEBF31Q33713824-8E05C125-DA57-4AA9-B5A7-8F8CFFCF903FQ33720628-C549AFEE-6E3A-49C0-99A3-92199CD67575Q33799437-AA83B382-FF17-45F5-A05D-D2D020A0936EQ33804845-1CA58C49-0069-45C4-B59C-527E2F85843FQ33816579-92F76647-5841-4584-9FBF-AC00DB124F61Q33827571-F8A59F9C-693E-42C9-9A85-F9BC86C6A633Q33851852-A6D59FDD-9BED-4DD3-AB11-CFECE75279EFQ33905047-D8902C55-3CA4-4071-82B9-26D6248193B5Q33995752-056ADD3C-56FA-4559-BA45-35C0DF4351E7Q34046125-F1D390BB-789A-4559-9F54-90A0D54FFB42Q34074791-D4E32CAA-47D3-4F73-A389-6EF55E8F1C82Q34139375-8B143044-0046-4F40-BB39-7592492ED5B8Q34302130-A5BFE204-1215-408D-B082-CC6AD86B1EECQ34374721-6AA59C9D-789F-4B95-BDEE-01DD73F1E8BCQ34423157-A319692E-C1D2-4FCC-BEAC-2B550AF5C721Q35051285-1A7D372B-CF91-4183-81D2-B4E2EC224C40Q35060701-50C76C01-0B49-4FC2-BF75-384F0F2BB3B3Q35116166-D8C94C90-A16C-433D-99A4-B5BFEDE1BEB6Q35126267-685FC33C-7A78-4D6C-91CE-A0668E5829C7Q35559877-D3E57184-63F9-4C8B-8EFA-FB08F6FEFAAAQ35613495-CE32EB16-051D-4379-A673-3DAA0AA61D21Q35673628-13B39012-3C77-4C21-8819-D31719DA962CQ35800497-CF824BD5-1DBA-47BE-822F-A5304012EF96Q35842604-734D4252-9203-45DB-843F-C56C2DFF1949Q35852258-8B95514F-399F-4EE2-8253-45C38E2B98C1Q35864136-1D2C3A56-142E-4376-AA76-C0DFD61CF522Q35888685-611B2DCB-E850-485D-8765-963D46D9C3E2Q35943736-8D8E72DB-8D59-4FFD-A228-956A2B57CB1FQ35945465-5D355E14-F240-4AAC-81E8-EE54039F912EQ36220799-2F2E610F-1935-47BA-99F4-190E37A719AFQ36288909-314E3A88-7C80-4040-86D9-76D519B7F6B8Q36318160-FF178B5B-791D-4A0D-BF06-5F2AB0FFD42DQ36444443-AFFADFC2-5F09-4BD9-8101-AC4551B2BB54Q36546412-5BCB5E8D-6F20-40D2-961A-AF673BA95C32Q36644898-002104E4-FCB6-4958-857D-5639DE245217
P2860
Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma.
description
1995 nî lūn-bûn
@nan
1995 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Comparison of genetically engi ...... del of human malignant glioma.
@ast
Comparison of genetically engi ...... del of human malignant glioma.
@en
Comparison of genetically engi ...... del of human malignant glioma.
@nl
type
label
Comparison of genetically engi ...... del of human malignant glioma.
@ast
Comparison of genetically engi ...... del of human malignant glioma.
@en
Comparison of genetically engi ...... del of human malignant glioma.
@nl
prefLabel
Comparison of genetically engi ...... del of human malignant glioma.
@ast
Comparison of genetically engi ...... del of human malignant glioma.
@en
Comparison of genetically engi ...... del of human malignant glioma.
@nl
P2093
P2860
P356
P1476
Comparison of genetically engi ...... del of human malignant glioma.
@en
P2093
G Y Gillespie
L Soroceanu
R Chambers
R J Whitley
S Andreansky
S Chatterjee
P2860
P304
P356
10.1073/PNAS.92.5.1411
P407
P577
1995-02-01T00:00:00Z